In 2018, Mao et al. and Ni et al. reported [33,34] the first example of dual-target inhibitors for AChE and PDE5 as potentially novel therapeutic agents for the treatment of Alzheimer’s disease (AD). Here, PDE5A is linked to Alzheimer disease.